Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B.

ABSTRACT: The most relevant endpoint in therapeutic HIV vaccination is the assessment of time to viral rebound or duration of sustained control of low-level viremia upon cART treatment cessation. Structured treatment interruptions (STI) are however not without risk to the patient and reliable predictors of viral rebound/control after therapeutic HIV-1 vaccination are urgently needed to ensure patient safety and guide therapeutic vaccine development. Here, we integrated immunological and virological parameters together with viral rebound dynamics after STI in a phase I therapeutic vaccine trial of a polyvalent MVA-B vaccine candidate to define predictors of viral control. Clinical parameters, proviral DNA, host HLA genetics and measures of humoral and cellular immunity were evaluated. A sieve effect

SUBMITTER: Rosas-Umbert M 

PROVIDER: S-EPMC5617163 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature